Johnson & Johnson (JNJ) – VARIPULSE Pro has officially entered the European market, marking a significant milestone in the evolution of pulsed field ablation (PFA) technology. Johnson & Johnson MedTech announced the launch of this next-generation platform following its CE Mark approval, signaling a new era of efficiency for electrophysiologists treating atrial fibrillation (AFib).
As the prevalence of AFib continues to rise, affecting more than 50 million people globally, the demand for advanced cardiovascular solutions that prioritize both safety and speed has never been higher. The introduction of this platform is a direct response to the need for more streamlined clinical workflows in over-burdened healthcare systems.
VARIPULSE Pro: Enhancing Procedural Efficiency with Advanced Pulse Sequences
The standout feature of the VARIPULSE Pro platform is its newly engineered pulse sequence. This innovation allows for a lower temperature profile during procedures, which is critical for maintaining the safety standards that the VARIPULSE line is known for. Remarkably, the system enables ablation that is five times faster than the previous sequence, significantly reducing the time patients spend in the procedure room while achieving equivalent, durable lesions.
Integration with the CARTO 3 System
A key differentiator for VARIPULSE Pro is its seamless integration with the CARTO 3 System, the world’s leading 3D cardiac mapping technology. This integration provides physicians with:
- Real-time Visualization: High-definition mapping that guides the catheter with extreme precision.
- Tissue Proximity Indicators: Data-driven feedback that ensures the catheter is correctly positioned before energy is delivered.
- Workflow Consistency: A unified platform that reduces the need for multiple disparate systems during complex ablations.
Read More: Johnson & Johnson to Acquire Halda Therapeutics for $3.05 Billion, Bolstering Oncology Pipeline
Clinical Evidence and the VARIPURE Study
Johnson & Johnson is backing this launch with rigorous scientific evidence. The company will feature the platform at the upcoming European Heart Rhythm Association (EHRA) 2026 annual meeting. During the summit, 12-month interim results from the VARIPURE study, a multicenter, prospective, postmarket follow-up study, will be presented to the global medical community.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
The Future of PFA at Johnson & Johnson
The launch of VARIPULSE Pro underscores Johnson & Johnson’s commitment to leading the science of PFA. By leveraging real-world learnings and scientific expertise, the company is not just releasing a product but evolving a platform that adapts to the needs of modern electrophysiology.
